Stock AnalizBausch & Lomb Corp BLCO
Ophthalmic Goods · IPO 2022 · data as of November 13, 2026
Bausch & Lomb Corp (BLCO) is a healthcare company listed in the US with a market value of about $7.5B. In the twelve months to September 30, 2026 it had revenue of $5.4B and net income of -$111M, a net margin of -2.0%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 29.9, 5-year revenue growth of 8% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.
Score: 1.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.4B | $5.1B | $4.8B | $4.1B | $3.8B | $3.8B | $3.4B |
| Net income | -$111M | -$360M | -$317M | -$260M | $6M | $182M | -$18M |
| Free cash flow | $252M | -$66M | -$59M | -$198M | $170M | $680M | $269M |
| EPS (diluted) | $-0.32 | $-1.02 | $-0.90 | $-0.74 | $0.02 | $0.52 | $-0.05 |
| Net margin | -2.0% | -7.1% | -6.6% | -6.3% | 0.2% | 4.8% | -0.5% |
| ROIC | — | 0.8% | 1.1% | 0.9% | 1.7% | 2.1% | 2.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $21.71, 3% above the current price; targets range from $18.00 to $26.00; the consensus rating is “Buy”; expected EPS is $0.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Bausch & Lomb stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bausch & Lomb pay a dividend?
Not currently.
Is Bausch & Lomb a good stock to buy?
We do not give buy or sell advice. Bausch & Lomb scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.